PD-L1-话题@MedSci

#PD-L1#

309篇内容 | 7268人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1254961, encodeId=9075125496183, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=JAMA Oncol：PD-L1表达可以预测免疫治疗疗效，PD-L1基因扩增呢？, objectType=article, longId=141402, objectId=21e01414028f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=21e01414028f, replyNumber=0, likeNumber=0, createdTime=2018-06-24, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=21e01414028f, moduleTitle=JAMA Oncol：PD-L1表达可以预测免疫治疗疗效，PD-L1基因扩增呢？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=21e01414028f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254960, encodeId=2d04125496055, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Nat Immunol：PD-1/PD-L1不响应机制被揭密，NK细胞其核心作用, objectType=article, longId=141325, objectId=cafd141325f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cafd141325f8, replyNumber=0, likeNumber=116, createdTime=2018-06-24, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cafd141325f8, moduleTitle=Nat Immunol：PD-1/PD-L1不响应机制被揭密，NK细胞其核心作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cafd141325f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254959, encodeId=e696125495944, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=ASCO速递：PD-L1表达可预测膀胱癌免疫治疗疗效, objectType=article, longId=139899, objectId=92ae13989904, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=92ae13989904, replyNumber=0, likeNumber=122, createdTime=2018-06-05, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=92ae13989904, moduleTitle=ASCO速递：PD-L1表达可预测膀胱癌免疫治疗疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=92ae13989904)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254958, encodeId=a3be1254958e6, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Lancet respir med：Tremelimumab（抗CTLA4单克隆抗体）联合durvalumab（抗PD-L1单克隆抗体）用于间皮瘤的疗效和安全性, objectType=article, longId=138186, objectId=481213818605, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=481213818605, replyNumber=0, likeNumber=115, createdTime=2018-05-16, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=481213818605, moduleTitle=Lancet respir med：Tremelimumab（抗CTLA4单克隆抗体）联合durvalumab（抗PD-L1单克隆抗体）用于间皮瘤的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=481213818605)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254957, encodeId=6507125495e04, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=PD-L1/ CTLA-4免疫联合治疗非小细胞肺癌未能获益, objectType=article, longId=136414, objectId=1d661364149a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1d661364149a, replyNumber=0, likeNumber=54, createdTime=2018-04-26, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1d661364149a, moduleTitle=PD-L1/ CTLA-4免疫联合治疗非小细胞肺癌未能获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1d661364149a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254956, encodeId=326f125495686, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Int Oral Max Surg：肿瘤PD-L1的表达与年轻女性口腔鳞状细胞癌生存期的改善及复发风险降低有关, objectType=article, longId=134603, objectId=74e21346033e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74e21346033e, replyNumber=0, likeNumber=102, createdTime=2018-04-10, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74e21346033e, moduleTitle=Int Oral Max Surg：肿瘤PD-L1的表达与年轻女性口腔鳞状细胞癌生存期的改善及复发风险降低有关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=74e21346033e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254955, encodeId=38201254955e3, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Lancet：震惊！PD-1/PD-L1免疫抑制剂或可出现致死性并发症！, objectType=article, longId=132932, objectId=7c6813293284, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c6813293284, replyNumber=0, likeNumber=65, createdTime=2018-03-21, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c6813293284, moduleTitle=Lancet：震惊！PD-1/PD-L1免疫抑制剂或可出现致死性并发症！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7c6813293284)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254954, encodeId=f446125495466, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=BMJ：抗PD-L1药物免疫相关的不良事件！, objectType=article, longId=132477, objectId=327f1324e704, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=327f1324e704, replyNumber=0, likeNumber=69, createdTime=2018-03-16, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=327f1324e704, moduleTitle=BMJ：抗PD-L1药物免疫相关的不良事件！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=327f1324e704)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254953, encodeId=304c12549534d, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=JCO：DNA损伤反应和修复基因改变作为晚期尿路上皮癌PD-1/PD-L1阻断获益的标志物, objectType=article, longId=131112, objectId=8a26131112d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8a26131112d7, replyNumber=0, likeNumber=88, createdTime=2018-03-03, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8a26131112d7, moduleTitle=JCO：DNA损伤反应和修复基因改变作为晚期尿路上皮癌PD-1/PD-L1阻断获益的标志物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8a26131112d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254952, encodeId=1e451254952a7, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=CLIN CANCER RES：头颈部肿瘤患者血浆PD-L1+外泌体的临床意义, objectType=article, longId=130922, objectId=91761309222a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=91761309222a, replyNumber=0, likeNumber=88, createdTime=2018-03-02, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=91761309222a, moduleTitle=CLIN CANCER RES：头颈部肿瘤患者血浆PD-L1+外泌体的临床意义, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=91761309222a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254951, encodeId=8f6212549516f, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=J Thorac Oncol:肺癌胸腔积液细胞PD-L1表达是肺癌患者免疫治疗的预后指标吗？, objectType=article, longId=130869, objectId=aaa31308691f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aaa31308691f, replyNumber=0, likeNumber=91, createdTime=2018-03-01, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aaa31308691f, moduleTitle=J Thorac Oncol:肺癌胸腔积液细胞PD-L1表达是肺癌患者免疫治疗的预后指标吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aaa31308691f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254950, encodeId=22b7125495027, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=CLIN CANCER RES：血管靶向光动力疗法可以增强PD-1/PD-L1通路阻滞抗肿瘤免疫反应, objectType=article, longId=130628, objectId=2e681306281d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2e681306281d, replyNumber=0, likeNumber=99, createdTime=2018-02-27, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2e681306281d, moduleTitle=CLIN CANCER RES：血管靶向光动力疗法可以增强PD-1/PD-L1通路阻滞抗肿瘤免疫反应, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2e681306281d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254949, encodeId=5be312549495c, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=JCO：非小细胞肺癌患者抗PD-1/PD-L1阻断治疗反应的分子决定因素, objectType=article, longId=126847, objectId=ac8812684e25, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ac8812684e25, replyNumber=0, likeNumber=67, createdTime=2018-01-20, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ac8812684e25, moduleTitle=JCO：非小细胞肺癌患者抗PD-1/PD-L1阻断治疗反应的分子决定因素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ac8812684e25)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254948, encodeId=6c4d125494840, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Nature：CD4/6抑制剂通过增加PD-L1表达提高免疫检查点抑制剂的治疗效果, objectType=article, longId=125917, objectId=6df412591ef3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6df412591ef3, replyNumber=0, likeNumber=65, createdTime=2018-01-10, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6df412591ef3, moduleTitle=Nature：CD4/6抑制剂通过增加PD-L1表达提高免疫检查点抑制剂的治疗效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6df412591ef3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254947, encodeId=05eb125494e83, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=J Clin Oncol：PD-L1免疫组化检测：NSCLC中的分析及临床应用, objectType=article, longId=124802, objectId=d02e124802f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d02e124802f2, replyNumber=0, likeNumber=75, createdTime=2017-12-28, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d02e124802f2, moduleTitle=J Clin Oncol：PD-L1免疫组化检测：NSCLC中的分析及临床应用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d02e124802f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254946, encodeId=4cb61254946e0, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Oncotarget：PD-1 / PD-L1免疫检查点的小分子抑制剂能够减轻PD-L1诱导的T细胞耗竭, objectType=article, longId=124231, objectId=8f861242312e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f861242312e, replyNumber=0, likeNumber=93, createdTime=2017-12-23, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f861242312e, moduleTitle=Oncotarget：PD-1 / PD-L1免疫检查点的小分子抑制剂能够减轻PD-L1诱导的T细胞耗竭, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8f861242312e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254945, encodeId=7ff612549453d, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Lancet：Atezolizumab不能延长PD-L1过表达的铂难治性转移性尿路上皮癌患者生存期, objectType=article, longId=123956, objectId=a774123956b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a774123956b5, replyNumber=0, likeNumber=68, createdTime=2017-12-21, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a774123956b5, moduleTitle=Lancet：Atezolizumab不能延长PD-L1过表达的铂难治性转移性尿路上皮癌患者生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a774123956b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254944, encodeId=111112549446f, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Clin Cancer Res：头颈部肿瘤患者血浆中PD-L1 +外泌体的临床意义, objectType=article, longId=123725, objectId=e13d123e25fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e13d123e25fc, replyNumber=0, likeNumber=94, createdTime=2017-12-18, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e13d123e25fc, moduleTitle=Clin Cancer Res：头颈部肿瘤患者血浆中PD-L1 +外泌体的临床意义, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e13d123e25fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254943, encodeId=6977125494345, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=JCO：派姆单抗治疗晚期PD-L1阳性宫颈癌患者效果佳, objectType=article, longId=122519, objectId=7e5f122519c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7e5f122519c5, replyNumber=0, likeNumber=0, createdTime=2017-12-08, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7e5f122519c5, moduleTitle=JCO：派姆单抗治疗晚期PD-L1阳性宫颈癌患者效果佳, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7e5f122519c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254942, encodeId=fa0812549428e, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Lancet oncol：Avelumab，抗PD-L1单克隆抗体，为对铂类不敏感的转移性尿路上皮癌患者带来新的希望。, objectType=article, longId=122363, objectId=cb2d122363b2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb2d122363b2, replyNumber=0, likeNumber=85, createdTime=2017-12-07, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb2d122363b2, moduleTitle=Lancet oncol：Avelumab，抗PD-L1单克隆抗体，为对铂类不敏感的转移性尿路上皮癌患者带来新的希望。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cb2d122363b2)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

PD-L1

2020-05-29

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

JAMA Oncol：PD-L1表达可以预测免疫治疗疗效，PD-L1基因扩增呢？

2018-06-24

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Nat Immunol：PD-1/PD-L1不响应机制被揭密，NK细胞其核心作用

2018-06-24

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

ASCO速递：PD-L1表达可预测膀胱癌免疫治疗疗效

2018-06-05

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Lancet respir med：Tremelimumab（抗CTLA4单克隆抗体）联合durvalumab（抗PD-L1单克隆抗体）用于间皮瘤的疗效和安全性

2018-05-16

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

PD-L1/ CTLA-4免疫联合治疗非小细胞肺癌未能获益

2018-04-26

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Int Oral Max Surg：肿瘤PD-L1的表达与年轻女性口腔鳞状细胞癌生存期的改善及复发风险降低有关

2018-04-10

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Lancet：震惊！PD-1/PD-L1免疫抑制剂或可出现致死性并发症！

2018-03-21

仁医06 (审核中...)

前往app查看评论内容

#PD-L1#

BMJ：抗PD-L1药物免疫相关的不良事件！

2018-03-16

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

JCO：DNA损伤反应和修复基因改变作为晚期尿路上皮癌PD-1/PD-L1阻断获益的标志物

2018-03-03

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

CLIN CANCER RES：头颈部肿瘤患者血浆PD-L1+外泌体的临床意义

2018-03-02

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

J Thorac Oncol:肺癌胸腔积液细胞PD-L1表达是肺癌患者免疫治疗的预后指标吗？

2018-03-01

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

CLIN CANCER RES：血管靶向光动力疗法可以增强PD-1/PD-L1通路阻滞抗肿瘤免疫反应

2018-02-27

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

JCO：非小细胞肺癌患者抗PD-1/PD-L1阻断治疗反应的分子决定因素

2018-01-20

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Nature：CD4/6抑制剂通过增加PD-L1表达提高免疫检查点抑制剂的治疗效果

2018-01-10

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

J Clin Oncol：PD-L1免疫组化检测：NSCLC中的分析及临床应用

2017-12-28

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Oncotarget：PD-1 / PD-L1免疫检查点的小分子抑制剂能够减轻PD-L1诱导的T细胞耗竭

2017-12-23

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Lancet：Atezolizumab不能延长PD-L1过表达的铂难治性转移性尿路上皮癌患者生存期

2017-12-21

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Clin Cancer Res：头颈部肿瘤患者血浆中PD-L1 +外泌体的临床意义

2017-12-18

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

JCO：派姆单抗治疗晚期PD-L1阳性宫颈癌患者效果佳

2017-12-08

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Lancet oncol：Avelumab，抗PD-L1单克隆抗体，为对铂类不敏感的转移性尿路上皮癌患者带来新的希望。

2017-12-07

科室
- - 订阅+
  - 更多科室
工具
服务